PT-141 vs Cialis: how these two libido drugs actually differ

Last updated 2026-07-24

What is the basic difference between PT-141 and Cialis?

PT-141 is the research name for bremelanotide, a peptide that the FDA approved under the brand name Vyleesi in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women ^[1]. Cialis is the brand name for tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction in men. The core difference isn't dosing or price. It's where each drug works. PT-141 acts on the brain. Cialis acts on blood vessels. That single fact explains almost every other difference between them, including who they're approved for, what side effects show up, and why one is a shot and the other is a pill you can take on a schedule. PT-141 is a melanocortin receptor agonist, meaning it activates MC4R and related receptors that sit upstream of sexual desire circuits in the central nervous system ^[2]. Cialis doesn't touch the brain's desire circuitry at all. It blocks an enzyme (PDE5) in smooth muscle tissue, which lets more blood flow into the penis when a man is already aroused. No arousal signal, no effect. That's why Cialis is often described as a mechanical enabler of erections rather than a desire drug. A good way to think about it: Cialis helps the body respond to a signal that's already there. PT-141 is trying to generate the signal in the first place.

Is PT-141 approved for the same use as Cialis?

No. They're approved for different conditions in different sexes, and that matters more than most comparisons suggest. Vyleesi (bremelanotide/PT-141) carries FDA approval specifically for acquired, generalized HSDD in premenopausal women, based on two identical randomized phase 3 trials (the RECONNECT studies) ^[3]. Those trials measured desire using validated scales and found statistically significant improvement over placebo, though the actual effect size was modest, a point critics have pushed on hard ^[4]. Cialis is approved for erectile dysfunction in men, and separately for benign prostatic hyperplasia symptoms. It has no FDA approval for female sexual dysfunction and no approval related to desire in either sex. So the honest comparison isn't 'which works better for low libido.' It's 'these solve two different clinical problems, in different bodies, and were never tested head to head because they aren't interchangeable.' Anyone marketing PT-141 as a 'female Cialis' is oversimplifying a genuinely different mechanism ^[5].

How does PT-141's brain mechanism actually work?

PT-141 is thought to work through the central melanocortin system, particularly MC4R, a receptor involved in appetite, energy balance, and sexual motivation circuits in the hypothalamus ^{[2] [6]}. Activating these receptors appears to increase spontaneous sexual desire rather than simply improving physical response to stimulation. This central mechanism is also why bremelanotide has drawn research interest outside of sexual medicine. The same melanocortin pathway is being studied for metabolic disorders including obesity ^[6], and one phase 1 dataset found bremelanotide was associated with weight changes in obese women taking it for other reasons . Researchers have also looked at melanocortin receptor agonism in contexts as different as glioblastoma cell studies , which highlights that this is a receptor system with effects well beyond the bedroom, not a narrow 'libido switch.' A 2022 review in CNS Spectrums lays out the neurobiological argument for why a brain-acting drug makes sense for HSDD specifically, since the disorder is defined by low sexual interest and arousability rather than by inadequate blood flow ^[6]. That's a fundamentally different problem than erectile dysfunction, which is why a vascular drug like Cialis was never going to be the right tool for HSDD in the first place.

How well does PT-141 work compared to Cialis for its approved use?

You can't directly compare efficacy numbers because the trials measured different things in different populations for different conditions. But it helps to look at what each drug's own trial data actually shows. The RECONNECT phase 3 trials tested bremelanotide 1.75 mg self-injected as needed, at least 45 minutes before anticipated sexual activity, in premenopausal women with HSDD ^[3]. The trials found statistically significant improvement in desire and reduction in distress compared to placebo. But a 2024 Journal of Sex Research analysis titled 'Small Effects, Questionable Outcomes' argued the actual clinical meaningfulness of that improvement is debatable, since the placebo response was substantial and the absolute gain over placebo was small ^[4]. A separate re-analysis in the same journal raised similar concerns about how HSDD outcomes were defined and measured in the registration trials . Cialis's ED trials, by contrast, measure erectile function using the International Index of Erectile Function and consistently show large, well-replicated improvements in erection quality and successful intercourse rates in men with vascular or mixed-etiology ED. That's a much more mechanically direct outcome to measure than 'desire,' which is inherently harder to quantify and more placebo-responsive. A 2021 Drug and Therapeutics Bulletin piece went as far as to argue that regulators shouldn't treat bremelanotide and flibanserin (another HSDD drug) as having earned their approvals on equivalent footing to established male sexual dysfunction drugs, calling the comparison a 'fallacy of regulatory precedent' ^[7]. That's a minority but serious position in the literature, and readers deciding whether PT-141 is worth trying should know this debate exists rather than assume the science is settled.

What side effects does PT-141 cause, and how do they compare to Cialis?

PT-141's most common side effects are nausea, flushing, and headache, and nausea in particular is frequent enough that it shapes how the drug is prescribed and dosed ^{[8] [9]}. A pooled safety analysis across the bremelanotide clinical development program found nausea was the most commonly reported adverse event, with flushing and injection site reactions also common, and these effects tend to be dose-related and more pronounced with early or repeated dosing ^[8]. Cialis's side effect profile is different: headache, back pain, muscle aches, flushing, and nasal congestion are typical, and because it's a vasodilator, it carries specific cardiovascular cautions, especially the well-known interaction with nitrate medications, which can cause dangerous drops in blood pressure. | Feature | PT-141 (bremelanotide/Vyleesi) | Cialis (tadalafil) |

Does PT-141 affect blood pressure like Cialis does?

Both drugs interact with cardiovascular physiology, but in opposite directions and through different mechanisms. Cialis lowers vascular resistance and can cause dangerous hypotension when combined with nitrates. PT-141 can cause a transient rise in blood pressure and a slight drop in heart rate after dosing, which is why product labeling advises caution in patients with uncontrolled hypertension or known cardiovascular disease . A 2022 review in Medicina (Kaunas) specifically looked at managing hypertension in the context of female sexual dysfunction treatment, emphasizing that blood pressure status is a real variable clinicians need to screen for before prescribing bremelanotide, more than an ED consideration . This is a case where combining the two drugs, or substituting one for the other without medical guidance, isn't a good idea. If you have a cardiovascular condition, that's a conversation for a prescriber, not a guess based on which drug sounds milder.

Can men use PT-141 the way women use it for HSDD?

PT-141 has FDA approval only for premenopausal women with HSDD. It is not FDA-approved for men, and there's no approved indication for male sexual dysfunction under the Vyleesi label ^{[1] [10]}. That said, bremelanotide's history includes earlier research in men. Early development work (originally as PT-141, before the Vyleesi approval) explored effects on erectile function in men, building on melanocortin receptor research from the 2000s ^{[11] [12]} . Some compounded or research-use PT-141 products marketed online reference this history, but compounded bremelanotide sold outside the approved Vyleesi pathway isn't FDA-reviewed for safety or effectiveness in men, and bremelanotide isn't on the FDA's 503A bulk drug substances list for compounding [reference 21 CFR 216.23], meaning it sits in a legally murky space for compounders . If you're a man considering PT-141 for erectile or desire concerns, the honest answer is that it's not the approved tool for that job. Cialis and other PDE5 inhibitors remain the FDA-approved, well-studied option for male ED. Anyone offering PT-141 as an off-label male libido fix should be able to explain that it's outside its approved use, not present it as an established alternative.

Can PT-141 and Cialis be used together?

There's no FDA-approved combination protocol for bremelanotide and tadalafil, and because they work through unrelated systems (central desire vs. peripheral blood flow), any decision to combine them needs a prescriber's involvement, not a guess based on 'different mechanisms means safe together.' Both drugs can independently affect blood pressure and heart rate, in opposite directions, and stacking anything that affects cardiovascular tone deserves real medical oversight, especially for anyone with existing heart or blood pressure issues . If a prescriber is managing a couple where one partner has ED and the other has low desire, that's a legitimate reason to discuss both drugs, but it should happen under clinical supervision, not through self-directed combining of an injection and a pill sourced separately.

How is PT-141 dosed compared to Cialis?

PT-141 (Vyleesi) is dosed as a 1.75 mg subcutaneous self-injection, taken as needed roughly 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours and no more than 8 doses per month per the approved regimen studied in the RECONNECT trials ^[3] . It's not a daily drug, and taking it more often than recommended increases nausea and flushing without proven added benefit. Cialis has two dosing patterns: an as-needed tablet (commonly 10 mg or 20 mg) taken before anticipated activity, or a low daily dose (commonly 2.5 mg or 5 mg) taken every day regardless of anticipated activity, which keeps a steady low level in the system so spontaneity isn't tied to timing a pill. That daily-dosing option is one of Cialis's practical advantages for couples who don't want to plan around a specific window. PT-141 doesn't have a daily-use approval; it's strictly an as-needed injection under its current label. For exact dosing schedules, injection technique, and how to handle missed or doubled doses, see our PT-141 dosage chart and PT-141 peptide how to use guide. If you're trying to figure out dose adjustments for body weight or response, a PT-141 dosage calculator can help frame the conversation with a prescriber, though it doesn't replace one.

How fast does each drug work, and how long does it last?

PT-141 is dosed about 45 minutes before anticipated activity, and its effects on desire are not immediate or guaranteed within a fixed window; the RECONNECT trial protocol built in that lead time based on pharmacokinetics observed in earlier studies ^[3] . Cialis's onset is typically within 30 minutes to 2 hours for the as-needed dose, and its defining feature versus other PDE5 inhibitors is duration: effects can last up to 36 hours, which is why it earned the nickname 'the weekend pill' in clinical marketing. Daily low-dose Cialis skips the onset-window question entirely since it's maintained continuously. Neither drug is an instant, guaranteed switch. Cialis still requires sexual stimulation to produce an erection; it doesn't create arousal on its own. PT-141 doesn't guarantee desire will appear on command either, and clinical reviewers have been clear that its trial effect sizes, while statistically real, are modest ^[4] .

Is PT-141 or Cialis the right choice for me?

This isn't really a 'which is better' question, because they're built for different problems. If you're a man with erectile difficulty and normal libido, Cialis (or another PDE5 inhibitor) is the evidence-based, FDA-approved starting point. PT-141 has no approved role there. If you're a premenopausal woman with persistently low sexual desire that's causing distress, and other causes (relationship issues, depression, medication side effects, hormonal factors) have been ruled out or addressed, bremelanotide is one of exactly two FDA-approved drugs for HSDD (the other being flibanserin), and it's worth discussing with a prescriber who can walk through the modest but real trial data ^{[1] [9] [3]}. What you shouldn't do is pick one drug because you've heard it's 'the female version' of the other. The mechanisms don't map that way, the approvals don't overlap, and self-directing treatment based on that assumption skips the screening (blood pressure, cardiovascular history, other medications) that actually matters for safety . A provider-reviewed telehealth pathway that checks your history before prescribing, rather than a source that just ships product, is the safer way to start either drug. Bremelanotide RX works with a provider-reviewed process and a licensed fulfilling pharmacy partner for exactly that reason, so dosing and screening happen before anything ships.

What does the research say about long-term use and unresolved questions?

Bremelanotide's approval rests on two phase 3 trials plus a supporting safety database, but the drug is still relatively new (FDA approval came in 2019) and long-term, real-world data is thinner than for a drug like Cialis, which has been on the market since 2003 ^{[10] [3]}. Ongoing academic debate continues about how much clinical benefit bremelanotide actually delivers above placebo, with multiple re-analyses in the Journal of Sex Research pushing back on the size and durability of the treatment effect reported in the original trials ^[4] . That's a healthy, normal part of how a new drug class gets scrutinized, and it doesn't mean the drug doesn't work; it means the effect is real but smaller than marketing sometimes implies. Separately, melanocortin receptor biology is an active research area well beyond sexual medicine, touching metabolic disease ^[6], inflammatory conditions linked to melanocortin receptor gene variants ^[13], and even early oncology cell research . None of that changes bremelanotide's approved use today, but it does mean the melanocortin system is getting more research attention, which could shape future drugs in ways Cialis's PDE5 pathway, a much older and more thoroughly mapped mechanism, generally won't.

Frequently asked questions

Is PT-141 the female version of Cialis?

Not really. Cialis is a PDE5 inhibitor that improves blood flow for erections in men. PT-141 is a melanocortin receptor agonist that acts in the brain to increase sexual desire, and it's FDA-approved as Vyleesi for HSDD in premenopausal women. They work through completely different biological systems and aren't interchangeable by sex.

Can women take Cialis instead of PT-141?

Cialis isn't FDA-approved for any female sexual dysfunction indication. It's built to increase blood flow for erectile function, which isn't the physiological problem HSDD addresses. Some off-label use in women has been studied for other conditions, but it's not an approved or established treatment for low sexual desire.

Does PT-141 cause the same nausea and flushing as Cialis?

Both can cause flushing, but through different mechanisms, and PT-141's nausea rate is notably higher and more prominent in its clinical trial data than Cialis's typical side effect profile. Nausea is the most commonly reported adverse event across bremelanotide's clinical development program.

Which works faster, PT-141 or Cialis?

Cialis as-needed dosing typically shows effect within 30 minutes to 2 hours and can last up to 36 hours. PT-141 is dosed about 45 minutes before anticipated activity per its trial protocol, but it affects desire rather than producing an immediate, guaranteed physical response.

Can I take PT-141 and Cialis together?

There's no FDA-approved combined protocol for this, and both drugs can affect blood pressure and heart rate, in opposite directions. Any decision to use them together should go through a prescriber who can review your cardiovascular history, not a self-directed combination.

Is PT-141 FDA-approved, like Cialis is?

Yes, bremelanotide is FDA-approved under the brand name Vyleesi, specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women, based on two phase 3 randomized trials. Cialis (tadalafil) is separately FDA-approved for erectile dysfunction and BPH symptoms in men.

Does PT-141 raise blood pressure like some ED drugs lower it?

PT-141 can cause a transient rise in blood pressure and slight drop in heart rate after dosing, which is the opposite direction from Cialis's vasodilating, blood-pressure-lowering effect. This is why prescribers screen for uncontrolled hypertension before prescribing bremelanotide.

Is PT-141 a pill like Cialis?

No. Vyleesi (bremelanotide) is a subcutaneous self-injection dosed as needed, roughly 45 minutes before anticipated sexual activity. Cialis is an oral tablet, available as an as-needed dose or a daily low-dose option.

How often can you use PT-141 versus Cialis?

PT-141's studied regimen allows one dose per 24 hours with a cap around 8 doses per month. Cialis can be taken as needed before activity, or as a low daily dose taken every day, which is an option PT-141 doesn't currently have under its approved label.

Does PT-141 actually work better than placebo?

Yes, statistically, in the RECONNECT phase 3 trials, but multiple published re-analyses argue the real-world clinical meaningfulness of that improvement over placebo is modest and worth discussing honestly with a prescriber rather than assuming a dramatic effect.

Can men use PT-141 for erectile dysfunction instead of Cialis?

PT-141 has no FDA approval for male sexual dysfunction. Earlier development work explored effects in men, but the current approved indication (Vyleesi) is specifically for premenopausal women with HSDD. Cialis remains the FDA-approved, well-studied option for male ED.

Where can I buy PT-141 legitimately compared to Cialis?

Cialis is widely available by prescription through standard pharmacies. PT-141 (Vyleesi) requires a prescription too, and bremelanotide isn't on the FDA's 503A bulk compounding list, so sourcing it outside a legitimate, provider-reviewed prescribing pathway carries real quality and legal uncertainty.

Sources

1. PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide was FDA-approved under the brand Vyleesi for HSDD in premenopausal women
2. PubMed, Bremelanotide (2006 record): Early bremelanotide development history included research in men prior to the female HSDD approval
3. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (2022): Nausea, flushing, and injection site reactions are the most commonly reported adverse events across bremelanotide's clinical program
4. PubMed, Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023): The central melanocortin system is being studied for metabolic disorders beyond sexual medicine
5. PubMed, Melanocortins in the treatment of male and female sexual dysfunction (2007): Bremelanotide activates melanocortin receptors including MC4R involved in sexual motivation circuits
6. PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (2020): Bremelanotide received FDA approval in 2019 and remains a relatively new drug with limited long-term real-world data
7. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022): Bremelanotide and flibanserin are the two FDA-approved drugs for HSDD
8. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): The RECONNECT phase 3 trials tested bremelanotide 1.75 mg self-injected as needed and found statistically significant improvement over placebo
9. PubMed, Bremelanotide (2012 record): Additional bremelanotide research record documenting drug development history
10. PubMed, Bremelanotide: the female Viagra? (Expert Review of Endocrinology & Metabolism, 2006): Bremelanotide has historically been compared to male sexual dysfunction drugs despite a distinct mechanism
11. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): A published critique argues regulators should not treat bremelanotide's approval as equivalent precedent to established male sexual dysfunction drugs
12. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022): Bremelanotide's central melanocortin mechanism is distinct from vascular approaches and is discussed as the neurobiological basis for treating HSDD
13. PubMed, Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases (2025): Melanocortin receptor gene variants are linked to inflammatory traits, showing the receptor system's relevance beyond sexual medicine
14. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024): A published analysis argues bremelanotide's clinical trial effect sizes over placebo are small and its outcomes are questionable
15. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Blood pressure status is a key screening variable before prescribing bremelanotide, and the drug can cause a transient blood pressure rise
16. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (2019): Bremelanotide dosing protocols in trials specified timing before anticipated sexual activity and dose-frequency limits
17. PubMed, Re-Analyzing Phase III Bremelanotide Trials for HSDD in Women (Journal of Sex Research, 2021): A re-analysis of the phase 3 trials raises concerns about how HSDD outcomes were measured and defined
18. PubMed, Effect of bremelanotide on body weight of obese women (Diabetes, Obesity & Metabolism, 2022): Phase 1 data found bremelanotide was associated with weight changes in obese women, reflecting its melanocortin pathway effects beyond desire
19. PubMed, Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells (Anticancer Research, 2024): Bremelanotide has been studied in early oncology cell research targeting melanocortin receptors in glioblastoma cells
20. eCFR, 21 CFR 216.23, the final 503A Bulks List: Bremelanotide is not listed on the FDA's 503A bulk drug substances list for compounding